405-39-0

Basic information

• Product Name: Z-LYS(Z)-OH
• Synonyms: DI-N-CBZ-L-LYSINE;DICARBOBENZOXY-L-LYSINE;Z-LYSINE(Z)-OH;Z-LYS(Z)-OH;N-ALPHA,EPSILON-BIS-Z-L-LYSINE;N-ALPHA,N-EPSILON-DI-Z-L-LYSINE;N-ALPHA, N-EPSILON-DIBENZYLOXYCARBONYL-L-LYSINE;N-ALPHA-N-EPSILON-DICARBOBENZOXY-L-LYSINE
• CAS NO: 405-39-0
• Molecular Formula: C₂₂H₂₆N₂O₆
• Molecular Weight: 414.45
• EINECS: 206-971-9
• Product Categories: Amino Acid Derivatives;Amino Acids & Derivatives;Aromatics;Intermediates;peptides
• Mol File: 405-39-0.mol

Chemical Properties

• Melting Point: 76-78°C
• Boiling Point: 659 °C at 760 mmHg
• Flash Point: 352.4 °C
• Appearance: White solid
• Density: 1.238 g/cm³
• Vapor Pressure: 2.9E-18mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: Store at RT.
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 3.97±0.21(Predicted)
• BRN: 1897206
• CAS DataBase Reference: Z-LYS(Z)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Z-LYS(Z)-OH(405-39-0)
• EPA Substance Registry System: Z-LYS(Z)-OH(405-39-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 405-39-0(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Protected L-lysine

InChI:InChI=1/C22H26N2O6/c25-20(26)19(24-22(28)30-16-18-11-5-2-6-12-18)13-7-8-14-23-21(27)29-15-17-9-3-1-4-10-17/h1-6,9-12,19H,7-8,13-16H2,(H,23,27)(H,24,28)(H,25,26)/t19-/m0/s1

Upstream product

• 55592-84-2 Nε-Cbz-lysine 
• 56-87-1 L-lysine 
• 501-53-1 benzyl chloroformate 
• 5335-05-7 chloromethyl benzoate 
• 21160-82-7 4-nitrophenyl N₂,N₆-bis[(phenylmethoxy)carbonyl]-L-lysinate 
• 657-27-2 L-Lysine hydrochloride 
• 19506-72-0 benzyl-8-quinolyl carbonate 
• 63842-04-6 sodium benzyloxycarbonyl thiosulfate 
• 32279-04-2 (p-hydroxyphenyl)dimethylsulfonium methyl sulfate 
• 1155-64-2 N₆-[(benzyloxy)carbonyl]-L-lysine 
• 923-27-3 D-lysine 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 144889-39-4 N₂,N₆-bis(benzyloxycarbonyl)lysine tert-butyl ester 
• 24498-31-5 (S)-methyl 2-amino-6-(benzyloxycarbonylamino)hexanoate 

Downstream Products

• 106386-19-0 N^α-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-N^ω-nitro-L-arginine methyl ester 
• 911664-89-6 Z-Lys(Z)-Gly-OMe 
• 17460-95-6 N-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-L-valine 
• 120176-22-9 N⁶-[N^2',N^6'-di(benzyloxycarbonyl)-L-lysyl]-L-lysine 
• 53613-40-4 N-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-L-tyrosine ethyl ester 
• 91307-61-8 N-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-L-tyrosine benzyl ester 
• 146754-64-5 benzyl N₆-((benzyloxy)carbonyl)-N₂-(N₂,N₆-bis((benzyloxy)carbonyl)-L-lysyl)-L-lysinate 
• 74283-31-1 di-Z-L-lysine hydrazide 
• 27894-50-4 methyl (2S)-2-amino-6-{[(benzyloxy)carbonyl]amino}hexanoate hydrochloride 
• 1676-86-4 N-benzyloxycarbonyl-L-lysine N-carboxyanhydride 
• 55461-90-0 N-(N²,N⁶-bis-benzyloxycarbonyl-lysyl)-N'-isonicotinoyl-hydrazine 
• 52126-91-7 Z(OMe)-Lys(Z)-Tyr-OMe 
• 195526-65-9 N-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-L-tyrosine amide 
• 13567-34-5 N_α,N_ξ-di-Cbz-L-lysylglycine ethyl ester 

Relevant articles and documents

DRUG-LOADED EMULSION

The present invention relates to a drug-loaded emulsion, comprising a modified hydrophobic excipient having the following formula, a hydrophobic drug and a surfactant: where R is a hydrophobic natural compound or a hydrophobic synthetic compound with one to three hydroxyl groups (n=1-3); and R1 is an α-amino protecting group, and R2 is an amino acid side chain, wherein, when m=0, R is reacted with an amino acid derivative with a protecting group by esterification to form a hydrophobic excipient carrying the amino acid derivative with a protecting group; or when m=1, R is firstly introduced with an amino acid linking arm of different chain lengths (l=1, 2, 4, 6) via an ester group, and then introduced with an amino acid derivative with a protecting group.

Phosphorylcholine compound Lys-PC containing propyl dimethicone and preparation method thereof

The invention discloses a phosphorylcholine compound Lys-PC containing propyl dimethicone and a preparation method thereof. The phosphorylcholine compound can be used as a surface treating agent or a raw material of the surface treating agent, can be directly used as a modifier for surfaces of various base materials or a chain extender and a cross-linking agent of modification of the base materials, can lower adsorption of protein, can improve the biocompatibility of high polymer materials by reducing adhesion and activation of blood platelets and has huge academic value and wide application prospects in the fields such as tissue engineering, controlled drug release, gene therapy and cosmetics. The steps are simple, the operation is convenient and the practicability is high.

A novel double-amino of the phosphorylcholine compound Lys - EG - PC and its preparation method (by machine translation)

The invention discloses a novel double-amino of the phosphorylcholine compound Lys - EG - PC and its preparation method. The purpose of this invention is to provide a can be used for surface treatment agent or surface treating agent raw material substance of the phosphorylcholine compound, such compounds can also be directly used as the modifier, a chain extender or cross-linking agent used for to various substrate to modify the surface of the substrate or modified, so as to improve the blood compatibility of the high molecular material, reduce protein adsorption, reduce cell precipitation, in tissue engineering, controlled drug delivery, gene therapy, in the field of cosmetics and the like has a great Academic value and broad application prospects. The step is simple, easy to operate, and the practicability is strong. (by machine translation)

CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self- immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Chemical dynamic kinetic resolution and S/R interconversion of unprotected α-amino acids

Reported herein is the first purely chemical method for the dynamic kinetic resolution (DKR) of unprotected racemic α-amino acids (α-AAs), a method which can rival the economic efficiency of the enzymatic reactions. The DKR reaction principle can be readily applied for S/R interconversions of α-AAs, the methodological versatility of which is unmatched by biocatalytic approaches. The presented process features a virtually complete stereochemical outcome, fully recyclable source of chirality, and operationally simple and convenient reaction conditions, thus allowing its ready scalability. A quite unique and novel mode of the thermodynamic control over the stereochemical outcome, including an exciting interplay between axial, helical, and central elements of chirality is proposed. A new player for DKR: Dynamic kinetic resolution of α-amino acids has been achieved upon complexation with nickel(II) and a chiral ligand derived from optically active bis(naphthyl)amine under thermodynamic control, thus affording excellent diastereoselectivities and chemical yields. The S to R interconversion of α-amino acids is also described.

A "catch-and-release" protocol for alkyne-tagged molecules based on a resin-bound cobalt complex for peptide enrichment in aqueous media

The development of new and mild protocols for the specific enrichment of biomolecules is of significant interest from the perspective of chemical biology. A cobalt-phosphine complex immobilised on a solid-phase resin has been found to selectively bind to a propargyl carbamate tag, that is, "catch", under dilute aqueous conditions (pH 7) at 4-°C. Upon acidic treatment of the resulting resin-bound alkyne-cobalt complex, the Nicholas reaction was induced to "release" the alkyne-tagged molecule from the resin as a free amine. Model studies revealed that selective enrichment of the alkyne-tagged molecule could be achieved with high efficiency at 4-°C. The proof-of-concept was applied to an alkyne-tagged amino acid and dipeptide. Studies using an alkyne-tagged dipeptide proved that this protocol is compatible with various amino acids bearing a range of functionalities in the side-chain. In addition, selective enrichment and detection of an amine derived from the "catch and release" of an alkyne-tagged dipeptide in the presence of various peptides has been accomplished under highly dilute conditions, as determined by mass spectrometry. Catch and release: The specific enrichment of alkyne-tagged molecules has been achieved by using cobalt beads. A cobalt complex bound to a resin was found to selectively "catch" a propargyl carbamate tag under dilute aqueous conditions (see scheme). Upon acidic treatment of the alkyne-cobalt complex, the Nicholas reaction was induced to "release" an amine. Studies using an alkyne-tagged dipeptide proved its compatibility with various amino acids and peptides under highly dilute conditions.

Synthesis of enantiopure free and N-benzyloxycarbonyl-protected 3-substituted homotaurines from naturally occurring amino acids

Enantiopure N-benzyloxycarbonyl-protected and free 3-substituted homotaurines were synthesized from naturally occurring amino acids via N-benzyloxycarbonyl protection, Arndt-Eistert homologation, reduction, esterification with thioacetic acid, and oxidation with performic acid. The current method is a convenient, practical, and salt-free method for the synthesis of enantiopure 3-substituted homotaurine with moderate to good yields.

Polymer surfactants for gene therapy applications

A composition and method capable of delivering pharmaceutical or biomedical materials includes a tri-block surfactant having a hydrophilic block, a charged water-soluble block and a hydrophobic block.

ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.